Hirsch L, Chanza NM, Farah S, et al. - Cabozantinib has considerable intracranial activity and an acceptable safety in patients with renal cell carcinoma and brain metastases.

• This is a cohort study of 88 patients with renal cell carcinoma and brain metastases treated in 15 institutions across 4 countries, and median age at cabozantinib initiation was 61 years (range, 34-81 years).

• In the cohort of patients with progressing brain metastases without concomitant brain-directed local therapy (cohort A), the intracranial response rate was 55%; vs 47% in the cohort of patients with stable or progressing brain metastases concomitantly treated by brain-directed local therapy (cohort B).

• The extracranial response rate, median time to treatment failure, and median overall survival were reported to be 48%, 8.9 months, and 15 months, respectively, in cohort A; these estimates were 38%, 9.7 months, and 16 months, respectively in cohort B.

• No unexpected toxic effects or neurological adverse events occurred in this study.